Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
J Pharm Biomed Anal ; 148: 324-333, 2018 Jan 30.
Article in English | MEDLINE | ID: mdl-29080413

ABSTRACT

Piperacillin-tazobactam is a beta-lactam/beta-lactamase combination antibiotic used in patients with moderate to severe infection. Dosing of piperacillin-tazobactam requires an understanding of this patient group to maximise the effectiveness of this antibiotic and limit a further emergence of resistant pathogens. This is the first method that measures piperacillin and tazobactam simultaneously, across this range of clinically-relevant biological matrices. The calibration line was linear across the concentration range of 0.5-500µg/mL for piperacillin and 0.625-62.5µg/mL for tazobactam. All validation testing for matrix effects, precision and accuracy, specificity and stability were within 15%. A calibration equivalence study was performed to investigate the suitability of applying calibration curves prepared in an alternative matrix, with a mean bias of -10.8% identified for the application of a calibration line prepared for tazobactam in plasma only. Bias for all other calibration lines prepared in alternate matrices was within the 5% acceptance criteria. The method was successfully applied to a pharmacokinetic study of a critically ill patient receiving renal replacement therapy, with the results included.


Subject(s)
Penicillanic Acid/analogs & derivatives , Piperacillin/blood , Piperacillin/urine , Calibration , Chromatography, High Pressure Liquid , Critical Illness , Humans , Penicillanic Acid/blood , Penicillanic Acid/urine , Piperacillin, Tazobactam Drug Combination , Plasma/chemistry , Renal Replacement Therapy/methods , Sensitivity and Specificity , Tandem Mass Spectrometry/methods , Tazobactam , Urine/chemistry
2.
Int J Antimicrob Agents ; 43(4): 343-8, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24612982

ABSTRACT

This prospective pharmacokinetic study aimed to describe plasma and interstitial fluid (ISF) pharmacokinetics of piperacillin and tazobactam in critically ill patients on continuous venovenous haemodiafiltration (CVVHDF). Piperacillin/tazobactam (4g/0.5g) was administered every 8h and CVVHDF was performed as a 3-3.5L/h exchange using a polyacrylonitrile filter with a surface area of 1.05m(2). Serial blood (pre- and post-filter), filtrate/dialysate, urine and ISF concentrations were measured. Subcutaneous tissue ISF concentrations were determined using microdialysis. A total of 407 samples were collected. Median peak plasma concentrations were 210.5 (interquartile range=161.5-229.0) and 29.4 (27.9-32.0) mg/L and median trough plasma concentrations were 64.3 (49.0-68.9) and 12.3 (7.7-13.7) mg/L for piperacillin and tazobactam, respectively. The plasma elimination half-life was 6.4 (4.6-8.7) and 7.3 (4.6-11.8) h, volume of distribution 0.42 (0.29-0.49) and 0.32 (0.24-0.36) L/kg, total clearance 5.1 (4.2-6.2) and 3.8 (3.3-4.2) L/h and CVVHDF clearance 2.5 (2.3-3.1) and 2.5 (2.3-3.2) L/h for piperacillin and tazobactam, respectively. The tissue penetration ratio or ratio of area under the concentration-time curve of the unbound drug in ISF to plasma (unbound AUCISF/AUCplasma) was ca. 1 for both piperacillin and tazobactam. This is the first report of concurrent plasma and ISF concentrations of piperacillin and tazobactam during CVVHDF. For the CVVHDF settings used in this study, a dose of 4.5g piperacillin/tazobactam administered evry 8h resulted in piperacillin concentrations in plasma and ISF >32mg/L throughout most of the dosing interval.


Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Penicillanic Acid/analogs & derivatives , Piperacillin/pharmacokinetics , Sepsis/drug therapy , Acute Kidney Injury/mortality , Acute Kidney Injury/therapy , Adolescent , Adult , Aged , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/urine , Critical Illness , Extracellular Fluid/chemistry , Female , Half-Life , Hemofiltration/adverse effects , Humans , Male , Middle Aged , Penicillanic Acid/blood , Penicillanic Acid/pharmacokinetics , Penicillanic Acid/therapeutic use , Penicillanic Acid/urine , Piperacillin/blood , Piperacillin/therapeutic use , Piperacillin/urine , Prospective Studies , Tazobactam , beta-Lactamase Inhibitors
3.
Antimicrob Agents Chemother ; 56(11): 5715-23, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22908169

ABSTRACT

Piperacillin in combination with tazobactam is one of the most commonly used intravenous antibiotics. There is evidence for a possible saturable elimination of piperacillin. Therefore, the saturable elimination and its impact on the choice of optimal dosage regimens were quantified. In a randomized crossover study, 10 healthy volunteers received 1,500 mg and 3,000 mg of piperacillin as 5-min intravenous infusion. Population pharmacokinetics based on plasma and urine data were determined utilizing NONMEM and S-ADAPT. Probabilities of target attainment (PTAs) were compared for different models and dosage regimens, based on the target time of the non-protein-bound concentration above the MIC of at least 50% of the dosing interval. Total clearance of piperacillin was 18% (geometric mean ratio, 90% confidence interval, 11 to 24%) lower (P < 0.01), and renal clearance was 24% (9 to 37%) lower (P = 0.02) at the high compared to the low dose. The final model included first-order nonrenal elimination and parallel first-order and mixed-order renal elimination. Nonrenal clearance was 5.44 liter/h (coefficient of variation, 18%), first-order renal clearance was 4.42 liter/h (47%), and the maximum elimination rate of mixed-order renal elimination was 219 mg/h (84%), with a Michaelis-Menten constant of 36.1 mg/liter (112%). Compared to models with saturable elimination, a linear model predicted up to 10% lower population PTAs for high-dose short-term infusions (6 g every 8 h) and up to 4% higher population PTAs for low-dose continuous infusions (6 g/day). While renal elimination of piperacillin was saturable at therapeutic concentrations, the extent of saturation of nonrenal clearance was small. The influence of saturable elimination on PTAs for clinically relevant dosage regimens was relatively small.


Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Penicillanic Acid/analogs & derivatives , Piperacillin/pharmacokinetics , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/urine , Cross-Over Studies , Female , Humans , Infusions, Intravenous , Male , Metabolic Clearance Rate , Monte Carlo Method , Nonlinear Dynamics , Penicillanic Acid/blood , Penicillanic Acid/pharmacokinetics , Penicillanic Acid/pharmacology , Penicillanic Acid/urine , Piperacillin/blood , Piperacillin/pharmacology , Piperacillin/urine , Tazobactam
4.
Br J Clin Pharmacol ; 66(5): 648-59, 2008 Nov.
Article in English | MEDLINE | ID: mdl-19032173

ABSTRACT

AIMS: To explore the extent, time course, site(s), mechanism and possible clinical relevance of the pharmacokinetic (PK) interaction between piperacillin and flucloxacillin. METHODS: A single-dose, randomized, six-way crossover study in 10 healthy volunteers where all subjects received all of the following as 5-min intravenous infusions: (i) 1.5 g piperacillin, (ii) 0.5 g flucloxacillin, (iii) 1.5 g piperacillin + 0.5 g flucloxacillin, (iv) 3 g piperacillin, (v) 1 g flucloxacillin, and (vi) 3 g piperacillin + 1 g flucloxacillin. Drug concentrations in plasma and urine were determined by high-performance liquid chromatography. WinNonlin was used for PK modelling and statistics. RESULTS: Piperacillin significantly decreased the renal clearance of flucloxacillin from 5.44 to 2.29 l h(-1) (medians, P < 0.01) and the nonrenal clearance of flucloxacillin from 2.67 to 1.80 l h(-1) (P < 0.01). The renal clearance of flucloxacillin was reduced to 45% (point estimate, 90% confidence interval 40 to 50%) and the nonrenal clearance to 66% (59, 73). The extent of interaction was larger at the higher doses. Competitive inhibition of tubular secretion by piperacillin was identified as the most likely mechanism for the decreased renal clearance of flucloxacillin. Piperacillin had a 15-times higher affinity for the renal transporter than flucloxacillin based on the molar ratio. Piperacillin PK was only slightly affected by flucloxacillin. CONCLUSIONS: Piperacillin inhibits renal and nonrenal elimination of flucloxacillin. This interaction seems clinically significant, as total clearance was reduced by a factor of 1.5 for the lower and 2.1 for the higher doses. PK interactions, especially with piperacillin, are likely to occur also with other beta-lactam combinations and might be useful to improve the effectiveness of antibacterial treatment.


Subject(s)
Anti-Bacterial Agents/pharmacology , Floxacillin/pharmacology , Kidney Tubules/metabolism , Piperacillin/pharmacology , Adult , Analysis of Variance , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/urine , Area Under Curve , Cross-Over Studies , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Interactions , Female , Floxacillin/blood , Floxacillin/urine , Humans , Infusions, Intravenous , Kidney Function Tests , Kidney Tubules/drug effects , Male , Metabolic Clearance Rate , Models, Chemical , Piperacillin/blood , Piperacillin/urine , Young Adult
5.
Farm Hosp ; 32(4): 199-207, 2008.
Article in Spanish | MEDLINE | ID: mdl-19128727

ABSTRACT

OBJECTIVE: Assesment of dosage deviations of three ss-lactam antibiotics eliminated through the kidneys (meropenem, piperacillin/tazobactam and cefepime) by comparison of two prediction formulae, Cockroft-Gault (CG) and Modification of Diet in Renal Disease (MDRD) with 24 h urinary creatinine clearance (CrCl(24h)), as a reference method. METHOD: 125 samples of 61 critically ill patients (each one with CG, MDRD y CrCl(24h) values) were classified in one of the five stages of the National Kidney Foundation (NKF) according to CrCl(24h). Dosage discrepancies for each antibiotic based on CG y MDRD were studied in reference to CrCl(24h) by percentage agreement and weighted kappa. At each of the NKF stages, daily dosage differences (Delta=DosisCG-DosisCrCl(24h); Delta=DosisMDRD-DosisCrCl(24h)) and percentage of samples with dosage discrepancies by CG and MDRD in reference to CrCl(24h) were calculated. RESULTS: There were no statistically significant differences between the two prediction formulae in respect to CrCl(24h), achieving good degrees of concordance. Deviation percentages fluctuated between 15.2% and 28% and occurred mainly by underdosing on stages 1 and 2 and by overdosing on stages 4 and 5. CONCLUSIONS: The two renal function prediction formulae can be indistinctly used to optimize the ss-lactam antibiotics dose regimen, CG being the easiest one.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/urine , Cephalosporins/administration & dosage , Cephalosporins/urine , Critical Illness , Kidney Function Tests/methods , Thienamycins/administration & dosage , Thienamycins/urine , Cefepime , Humans , Meropenem , Penicillanic Acid/administration & dosage , Penicillanic Acid/analogs & derivatives , Penicillanic Acid/urine , Piperacillin/administration & dosage , Piperacillin/urine , Piperacillin, Tazobactam Drug Combination , Retrospective Studies
6.
Drug Metab Dispos ; 35(3): 345-9, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17194717

ABSTRACT

Piperacillin metabolism and biliary excretion are different between humans and preclinical species. In the present study, piperacillin metabolites were characterized in bile and urine of healthy humans and compared with metabolites formed in vitro. Volunteers were administered 2 g of piperacillin IV; blood, urine, and duodenal aspirates (obtained via a custom-made oroenteric catheter) were collected. The metabolism of piperacillin in humans also was investigated in vitro using pooled human liver microsomes and sandwich-cultured human hepatocytes. Piperacillin and metabolites were estimated by high-performance liquid chromatography with tandem mass spectrometry detection. Piperacillin, desethylpiperacillin, and desethylpiperacillin glucuronide were detected in bile, urine, and human liver microsomal incubates. Similar to the in vivo results, desethylpiperacillin was formed and excreted into bile canaliculi of sandwich-cultured human hepatocytes. This is the first report of glucuronidation of desethylpiperacillin in vitro or in vivo. The clinical method employed in this study to determine biliary clearance of drugs also facilitates bile collection as soon as bile is excreted from the gallbladder, thereby minimizing the exposure of labile metabolites to the intestinal environment. This study exemplifies how a combination of in vitro and in vivo tools can aid in the identification of metabolites unique to the human species.


Subject(s)
Piperacillin/pharmacokinetics , Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/urine , Bile/chemistry , Female , Hepatocytes/metabolism , Humans , Male , Microsomes, Liver/metabolism , Piperacillin/urine
7.
Biol Pharm Bull ; 29(12): 2519-22, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17142994

ABSTRACT

In order to assess the beneficial mechanism of the concomitant use of imipenem (IPM) with piperacillin (PIPC) for the treatment of serious infectious diseases such as sepsis, the effects of PIPC on the uptake of IPM by rat renal cortical slices and on the plasma concentrations of IPM after intravenous infusion to rabbits were studied. The uptake of IPM by the rat renal cortical slices was significantly inhibited by p-aminohippurate, probenecid and PIPC whereas the uptake of PIPC by the slices was slightly decreased in the presence of IPM. When IPM was administered together with PIPC by 1-h infusion, the plasma concentrations of IPM were significantly increased during the infusion. These results imply that PIPC possibly interferes with the renal transport of IPM mediated by an organic anion transporter across the renal basolateral membranes, which leads to a longer period above the minimum inhibitory concentrations of IPM.


Subject(s)
Imipenem/pharmacology , Kidney/physiology , Piperacillin/pharmacology , Animals , Chromatography, High Pressure Liquid , Imipenem/administration & dosage , Imipenem/urine , Piperacillin/administration & dosage , Piperacillin/urine , Rabbits , Rats , Rats, Wistar
8.
Article in English | MEDLINE | ID: mdl-11206555

ABSTRACT

The fluorimetric property of the degrading products of piperacillin has been studied in detail. The studies on degrading pH, degrading time, detection alkalinity and other corresponding analytical parameters of acid degradation have been made. Then fluorometry of piperacillin was established by producing its stable fluorescent products. The detection limit for acid degradation analytical method is 2.34 ng/ml, the linear range is 7.80-4.0 x 10(2) ppb. The analytical sensitivity, precision and stability of degrading products of acid degradation are satisfactory, which has been used for the determination of the trace piperacillin in human serum and urine with satisfactory results.


Subject(s)
Penicillins/chemistry , Piperacillin/chemistry , Spectrometry, Fluorescence , Humans , Hydrogen-Ion Concentration , Molecular Structure , Penicillins/blood , Penicillins/urine , Piperacillin/blood , Piperacillin/urine
9.
J Chromatogr A ; 812(1-2): 213-20, 1998 Jul 03.
Article in English | MEDLINE | ID: mdl-9691320

ABSTRACT

High-performance liquid chromatographic methods have been developed for the determination of piperacillin and mezlocillin in human serum and urine samples. The methods involve ultrafiltration of samples followed by reaction with 1.5 M 1, 2, 4-triazole and 0.5 x 10(-3) M mercury (II) chloride in solution (pH 8.50) at 50 degrees C for 15 min. The resulting products were separated on a C18 column following stabilisation in an eluent containing sodium thiosulphate. They were detected at 323 nm for both penicillins. The methods have been applied to assays applied to assays of these penicillins in human serum and urine samples. The procedures, which permit the determination of penicillin concentration down to 0.1 microgram m1-1 in serum and 1 microgram m1-1 in urine samples, are specific to intact penicillins without interference from corresponding penicilloates [see J. Haginaka et al., Anal. Sci. 1 (1985) 73]. At concentrations of 1-500 micrograms ml-1 for each compound, the within- and between-day precisions were 1.8-4.8 and 3.7-6.9, respectively. The accuracy was ca. 100% for all samples assayed.


Subject(s)
Mezlocillin/analysis , Penicillins/analysis , Piperacillin/analysis , Calibration , Carbonic Anhydrase Inhibitors/pharmacology , Chromatography, High Pressure Liquid , Hydrogen-Ion Concentration , Indicators and Reagents , Mezlocillin/blood , Mezlocillin/urine , Penicillins/blood , Penicillins/urine , Piperacillin/blood , Piperacillin/urine , Reproducibility of Results , Solutions , Spectrophotometry, Ultraviolet , Temperature , Triazoles , Ultrafiltration
10.
Eur J Obstet Gynecol Reprod Biol ; 76(1): 21-7, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9481541

ABSTRACT

The safety/acceptability, blood pharmacokinetics and urinary excretion of the piperacillin-tazobactam (PPR-TZB) combination were studied in six patients between 25 1/7 and 31 5/7 weeks of amenorrhea. The combination was given for a materno-fetal infection due to susceptible organisms i.e. 4/0.5 g/6 h. Whenever possible, the trans-placental transfer (TPT) of the combination was assessed in several sub-compartments of the feto-placental unit i.e. maternal blood sample, cord blood, amniotic fluid, placenta tissue and fetal urine. Two series of nine blood samples were scheduled for each patient, i.e. on D1 (first dose) and D3 (at plateau). Samples were assayed by HPLC and data were analyzed by a non-compartmental method. Safety/acceptability of the treatment proved to be good. The kinetic behavior of both beta-lactams appeared to be identical. Evidence was found during pregnancy of an increase in Vss and Cl of the combination. These increases can be linked to a notable decrease in AUCs. The TPT of the combination was significant. Regarding other accessible compartments (i.e. placenta tissue, amniotic fluid and fetal urine), the ratio of PPR-TZB concentrations was invariably about 8. Maternal circulating levels of PPR-TZB were, by 4 h, less than the MIC of target organisms (i.e. < or = 8 micrograms/ml), both on D1 and at steady state. This raises the question of the pertinence of the dosage regimen. Regarding PPR, it is accepted that antibacterial protection is satisfactory when circulating concentrations are kept at a Css (steady state concentration) of the order of 20 micrograms/ml or more. PPR-TZB combination would be administered by continuous infusion i.e. 8 mg/min to obtain 3 h later a Css of more than 20 micrograms/ml. The daily dosage would then be 12/1.5 g instead of 16/2 g, which is also more satisfactory from a pharmaco-economic standpoint. This proposal must be validated in a sufficient number of patients and, could avoid disqualification of the combination PPR-TZB in the treatment of serious infections during certain pathological pregnancies.


Subject(s)
Drug Therapy, Combination/pharmacokinetics , Penicillins/pharmacokinetics , Placenta/metabolism , Pregnancy/metabolism , Adult , Amniotic Fluid/metabolism , Drug Therapy, Combination/blood , Drug Therapy, Combination/urine , Female , Fetal Blood/metabolism , Fetus/metabolism , Humans , Kinetics , Maternal-Fetal Exchange , Penicillanic Acid/analogs & derivatives , Penicillanic Acid/blood , Penicillanic Acid/pharmacokinetics , Penicillanic Acid/urine , Piperacillin/blood , Piperacillin/pharmacokinetics , Piperacillin/urine , Piperacillin, Tazobactam Drug Combination , beta-Lactamase Inhibitors
11.
J Chromatogr B Biomed Appl ; 682(1): 125-36, 1996 Jun 28.
Article in English | MEDLINE | ID: mdl-8832433

ABSTRACT

A high-performance liquid chromatographic (HPLC) method with ultraviolet (UV) absorbance was developed for the analysis of piperacillin-tazobactam (tazocillin), in plasma and urine. The detection was performed at 218 nm for tazobactam and 222 nm for piperacillin. The procedure for assay of these two compounds in plasma and of piperacillin in urine involves the addition of an internal standard (ceftazidime for tazobactam and benzylpenicillin for piperacillin) followed by a treatment of the samples with acetonitrile and chloroform. To quantify tazobactam in urine, diluted samples were analysed using a column-switching technique without internal standard. The HPLC column, LiChrosorb RP-select B, was equilibrated with an eluent mixture composed of acetonitrile-ammonium acetate (pH 5). The proposed technique is reproducible, selective, and reliable. The method has been validated, and stability tests under various conditions have been performed. Linear detector responses were observed for the calibration curve standards in the ranges 5-60 micrograms/ml for tazobactam, and 1-100 micrograms/ml for piperacillin and spans what is currently though to be the clinically relevant range for tazocillin concentrations in body fluids. The limit of quantification was 3 micrograms/ml for tazobactam and 0.5 microgram/ml for piperacillin in plasma and urine. Extraction recoveries from plasma proved to be more than 85%. Precision, expressed as C.V., was in the range 0.4-18%.


Subject(s)
Enzyme Inhibitors/blood , Enzyme Inhibitors/urine , Penicillanic Acid/analogs & derivatives , Penicillins/blood , Penicillins/urine , Piperacillin/blood , Piperacillin/urine , Chromatography, High Pressure Liquid , Circadian Rhythm , Drug Stability , Enzyme Inhibitors/chemistry , Humans , Linear Models , Penicillanic Acid/blood , Penicillanic Acid/chemistry , Penicillanic Acid/urine , Penicillins/chemistry , Piperacillin/chemistry , Reference Standards , Reproducibility of Results , Sensitivity and Specificity , Spectrophotometry, Ultraviolet , Tazobactam , Temperature
12.
Kansenshogaku Zasshi ; 66(1): 6-13, 1992 Jan.
Article in Japanese | MEDLINE | ID: mdl-1402064

ABSTRACT

Isepamicin (ISP) and piperacillin (PIPC) were shifted to the urinary concentration by employing an in vitro complicated cystitis model operated by a computer-controlled automatic simulator for urinary concentration, and administrated to bacteria in the urinary bladder model (Pseudomonas aeruginosa: P. aeruginosa, initial cell concentration: 10(7) cfu/ml). In this case, effects by single treatment with ISP or PIPC on cell number curves were examined. Further, significance of the combined treatment with ISP and PIPC were investigated by changing the order of each treatment. And following the results were obtained. 1. In a single treatment with PIPC the cell concentration was minimum (10(4) cfu/ml) at 9th hour after its treatment and thereafter, regrowth to the same level as the initial concentration was observed at 16th hour. 2. In the case of single treatment with ISP, the cell concentration became minimum (10(2) cfu/ml) at 13th hour after the treatment and raised to the same concentration as the initial one at 25th hour. 3. In the combined treatment, the cell concentration was minimum (less than 10(1) cfu/ml) at 26th hour in the case of prior treatment with ISP. Thereafter, regrowth was observed and the cell concentration at 42nd hour reached to the initial cell concentration. 4. In simultaneous treatment with ISP and PIPC, the cell concentration at 24th hour was minimum (10(1) cfu/ml) and reached to the same level as the initial one after regrowth. From these results, it was found that the combined treatment with ISP and PIPC caused more reduction of the cell concentration than either single treatment. Further, regrowth of the cells was suppressed for longer duration.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Computer Simulation , Cystitis/drug therapy , Gentamicins/administration & dosage , Piperacillin/administration & dosage , Drug Therapy, Combination , Gentamicins/pharmacokinetics , Gentamicins/urine , In Vitro Techniques , Piperacillin/pharmacokinetics , Piperacillin/urine
13.
Int J Clin Pharmacol Ther Toxicol ; 28(11): 462-70, 1990 Nov.
Article in English | MEDLINE | ID: mdl-2272706

ABSTRACT

The purpose of the present experimental and clinical work is to revisit the biliary pharmacokinetic properties of piperacillin. Whereas the up to now published data result from microbiological assays, this work was realized by high performance liquid chromatography. In the isolated and perfused rabbit liver model (n = 5; 3 h), the biliary level peaked at 1,013 +/- 305 micrograms/ml between 30 and 60 min. During the experiments, 56.7% and 10.8% of the administered piperacillin (10 mg) were respectively eliminated in bile and submitted to hepatic biotransformation. In man, a single 2 g i.v. dose was administered to 6 volunteers. The excretion measured in the duodenal fluid was 1,681 +/- 601 micrograms in 4 h (0.08% of the administered dose). In cholecystectomized patients (n = 10) provided with a T-drain, the biliary peak concentration was 211 +/- 64 micrograms/ml during the 2nd h, and the 24 h biliary elimination was 12,963 +/- 3,332 micrograms, representing 0.65% of the administered dose. The hepato-biliary clearance was 0.80 ml/min. On per-operatively collected serum, choledocal bile, gallbladder bile and gallbladder wall samples (n = 10 patients), the concentrations of piperacillin simultaneously measured 1 h after the i.v. administration of 2 g were respectively, 81.7 +/- 20.5, 382 +/- 110, 30.8 +/- 2.5 micrograms/ml and 10.5 +/- 2.6 micrograms/g.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Bile/metabolism , Duodenum/metabolism , Intestinal Secretions/metabolism , Liver/metabolism , Piperacillin/pharmacokinetics , Animals , Chromatography, High Pressure Liquid , Female , Humans , Injections, Intravenous , Male , Middle Aged , Piperacillin/administration & dosage , Piperacillin/blood , Piperacillin/urine , Rabbits
14.
J Chromatogr ; 496(1): 167-79, 1989 Nov 10.
Article in English | MEDLINE | ID: mdl-2556418

ABSTRACT

A gradient elution high-performance liquid chromatographic method is described for the analysis of the beta-lactamase inhibitor tazobactam (YTR-830H) and a semi-synthetic parenteral penicillin, piperacillin, in human plasma, serum, bile and urine. The assay for plasma, serum and bile involves deproteinization with acetonitrile and the removal of lipids with dichloromethane; urine is diluted with buffer. Separation and quantitation are achieved using a mobile phase based on ion-suppression chromatography on a C18 reversed-phase column with ultraviolet detection at 220 nm. The limit of quantitation for both compounds is 1.0 microgram/ml in plasma, serum and bile using a 0.2-ml sample and 50.0 micrograms/ml in urine using a 0.1-ml sample. The method has been validated by preparing and analyzing a series of fortified samples (range 1.0-200 micrograms/ml for each compound in plasma, serum and bile and 50.0-10,000 micrograms/ml for each compound in urine). Excellent linearity, accuracy, precision and recovery were obtained. The method was not interfered with by other endogenous components, nor by other commonly administered antibiotics such as amoxicillin, mezlocillin, cefometazole and cefotaxime. The assay has been successfully applied to the analysis of samples from pharmacokinetic studies in man and animals.


Subject(s)
Anti-Bacterial Agents/metabolism , Bile/analysis , Penicillanic Acid/metabolism , Piperacillin/metabolism , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/urine , Chromatography, High Pressure Liquid , Humans , Penicillanic Acid/blood , Penicillanic Acid/urine , Piperacillin/blood , Piperacillin/urine , Spectrophotometry, Ultraviolet , Tazobactam
15.
Jpn J Antibiot ; 41(9): 1295-303, 1988 Sep.
Article in Japanese | MEDLINE | ID: mdl-3241327

ABSTRACT

Biliary and urinary concentrations and recoveries of 3 different antibiotics (piperacillin (PIPC), cefbuperazone (CBPZ) and cefoperazone (CPZ], after intravenous bolus injection were studied using the crossover method with external cholecystostomies done in order to treat obstructive jaundice due to complete obstruction of the lower biliary tract; the concentrations of antibiotics in bile and urine were determined by means of a high performance liquid chromatography method. Drug concentrations and recoveries in the bile after intravenous injection of these antibiotics were at levels in the order of CPZ greater than CBPZ greater than PIPC. Since our patients were inflicted with various malignancies which made them impaired in terms of biliary excretion of antibiotics, the concentrations of those drugs in the bile were lower than those previously reported by several investigators. However, CBPZ and CPZ showed sufficient levels of excretion into the bile and their amounts were high enough when compared to the value of MIC 80% reported recently against Escherichia coli and Klebsiella pneumoniae, which are known to be main pathogens of biliary system infections. The excretion of CPZ into the bile was invariably found to be 2 times or more as high as the other 2 drugs tested. Concentrations and recoveries of the 3 antibiotics excreted into urine were similar to the cefotaxime excretion, of which into urine had been reported to be excellent. Thus, CBPZ and CPZ appeared to be effective against biliary system infections, even with blockage of antibiotics excretion into the bile.


Subject(s)
Bile/metabolism , Cefoperazone/pharmacokinetics , Cephamycins/pharmacokinetics , Cholecystostomy , Cholestasis/metabolism , Piperacillin/pharmacokinetics , Aged , Aged, 80 and over , Cefoperazone/administration & dosage , Cefoperazone/urine , Cephamycins/administration & dosage , Cephamycins/urine , Cholestasis/surgery , Female , Humans , Injections, Intravenous , Male , Piperacillin/administration & dosage , Piperacillin/urine , Time Factors
16.
J Chromatogr ; 431(1): 87-101, 1988 Sep 23.
Article in English | MEDLINE | ID: mdl-2853169

ABSTRACT

[2S-(2 alpha,3 beta,5 alpha)]-3-Methyl-7-oxo-3-(1H-1,2,3-triazol-1-yl- methyl)-4-thia-1-azabicyclo [3.2.0]-heptane-2-carboxylic acid 4,4-dioxide (YTR-830H) is a new beta-lactamase inhibitor and the combination therapy of this compound with piperacillin is now under study. For the determination of the beta-lactamase inhibitor and piperacillin in biological materials, plasma and visceral tissue homogenates were deproteinized, whereas diluted urine and filtered faeces homogenates were treated with a Sep-Pak C18 cartridge. In order to assay the inactive metabolite of beta-lactamase inhibitor, each sample was treated with a Sep-Pak C18 cartridge. Aliquots of each preparation were chromatographed using ion-pair and reversed-phase chromatographic techniques on a high-performance liquid chromatograph equipped with a UV detector, set at 220 nm. The detection limits of beta-lactamase inhibitor and piperacillin were 0.2 microgram/ml in plasma, 2.5-5.0 micrograms/ml in urine and 0.2-0.5 microgram/g in visceral tissue and faeces. Those of the metabolite were 1.0 microgram/ml in plasma, 2.5-5.0 micrograms/ml in urine and 1.0 microgram/g in visceral tissue and faeces. A precise and sensitive assay for the determination of the beta-lactamase inhibitor, its metabolite and piperacillin is described, and their stabilities in several media are reported.


Subject(s)
Penicillanic Acid/analysis , Piperacillin/analysis , beta-Lactamase Inhibitors , Animals , Chromatography, High Pressure Liquid , Dogs , Feces/analysis , Humans , Hydrogen-Ion Concentration , Indicators and Reagents , Penicillanic Acid/blood , Penicillanic Acid/urine , Piperacillin/blood , Piperacillin/urine , Rats , Species Specificity , Spectrophotometry, Ultraviolet , Tazobactam , Tissue Distribution
17.
Arzneimittelforschung ; 36(9): 1379-83, 1986 Sep.
Article in English | MEDLINE | ID: mdl-3539126

ABSTRACT

Piperacillin (T-1220, Pipracil) a semi-synthetic antibiotic was evaluated in a battery of genetic toxicology assays. The assays employed were: the microbial assay, the host mediated assay, the microbial assay incorporating urine samples from mice dosed with piperacillin, the in vivo cytogenetic assay, and the dominant lethal assay. In all assays, piperacillin produced consistent negative results indicating that piperacillin does not have mutagenic potential.


Subject(s)
Mutagens , Piperacillin/toxicity , Animals , Chromosome Aberrations/drug effects , Female , Genes, Dominant/drug effects , Genes, Lethal/drug effects , Mice , Mutagenicity Tests , Piperacillin/urine , Pregnancy , Rats , Salmonella typhimurium/genetics
18.
Dev Pharmacol Ther ; 9(2): 102-14, 1986.
Article in English | MEDLINE | ID: mdl-3956344

ABSTRACT

Twenty children ranging in age from 1 week to 19 years with documented or suspected bacterial infections arising outside the central nervous system were studied. Pharmacokinetic analysis was possible in 15 children; 8 after the first dose, 6 during steady-state conditions, and 4 on both occasions. Data were obtained utilizing noncompartmental pharmacokinetic methods. Peak piperacillin serum concentrations ranged from 51 to 232 mg/l and correlated directly (r = 0.75) with the dose administered. In children with normal renal function, there was an age-dependent decrease in elimination half-life and apparent steady-state volume of distribution, whereas plasma clearance increased logarithmically. All but 1 child responded favorably to piperacillin therapy, and 1 child with a urinary tract infection relapsed 10 days after discontinuation of the therapy. Although improved clinically, piperacillin monotherapy failed to eradicate pathogens in 2 children. No adverse clinical or biochemical effects were observed in any child.


Subject(s)
Bacterial Infections/drug therapy , Piperacillin/therapeutic use , Adolescent , Adult , Aging , Bacterial Infections/microbiology , Child , Child, Preschool , Female , Gram-Negative Bacteria/drug effects , Humans , Infant , Kinetics , Male , Models, Biological , Piperacillin/pharmacology , Piperacillin/urine , Urinary Tract Infections/drug therapy , Urinary Tract Infections/microbiology
19.
Pharmazie ; 40(5): 333-5, 1985 May.
Article in German | MEDLINE | ID: mdl-3929279

ABSTRACT

Two pulse polarographical methods for determination of the half-synthetic penicillin derivate piperacillin in serum and in urine are described. 3.7 X 10(-5) mol/l (20 micrograms/ml) can yet been proved in serum with the direct pulse polarographical determination. 1.85 X 10(-6) mol/l (1 microgram/ml) can quantitatively be determined after preceded hydrolysis. Both the methods are diffusion standards being well developed which can be evaluated in an adequate manner. The piperacillin concentrations determined by pulse polarography agree to the levels of the agar diffusion test. The precision is some reduced by the separations incorporated. Inspite of the hydrolysis, the pulse polarographical method of determination will offer more prompt and reliable results.


Subject(s)
Piperacillin/analysis , Chromatography, Thin Layer , Half-Life , Humans , Immunodiffusion , Piperacillin/blood , Piperacillin/urine , Polarography , Time Factors
20.
Arzneimittelforschung ; 35(7): 1099-104, 1985.
Article in English | MEDLINE | ID: mdl-4052146

ABSTRACT

In plasma and urine of 10 healthy volunteers after intravenous administration of 4 g mezlocillin and piperacillin, respectively, the parent compounds as well as degradation products were assayed by high-performance liquid chromatography. Ioxitalamic acid, a renal contrast medium, was administered simultaneously, in order to measure the glomerular filtration rate, and to control the collection of 24-h urine. As metabolite of mezlocillin the corresponding penicilloic acid only was found, whereas in the case of piperacillin a further degradation product was observed. Half of the doses given was recovered in the urine as unchanged drugs, and in addition 5-10% as metabolites. No differences were found in the pharmacokinetic behaviour of both antibiotics.


Subject(s)
Iothalamic Acid/analogs & derivatives , Mezlocillin/analysis , Piperacillin/analysis , Adult , Chromatography, High Pressure Liquid , Female , Humans , Iothalamic Acid/analysis , Iothalamic Acid/blood , Iothalamic Acid/urine , Kinetics , Male , Mezlocillin/blood , Mezlocillin/urine , Piperacillin/blood , Piperacillin/urine
SELECTION OF CITATIONS
SEARCH DETAIL
...